The precise identification of Human Leukocyte Antigen class I (HLA-I) binding motifs plays a central role in our ability to understand and predict (neo-)antigen presentation in infectious diseases and cancer. Here, by exploiting co-occurrence of HLA-I alleles across ten newly generated as well as forty publicly available in-depth HLA peptidomics datasets, we show that we can rapidly and accurately identify HLA-I binding motifs and map them to their corresponding alleles without any a priori knowledge of HLA-I binding specificity. Our novel approach uncovers new motifs for several alleles that up to now had no known ligands. HLA-ligand predictors trained on such data substantially improve neo-antigen predictions in four melanoma and two lung cancer patients, indicating that unbiased HLA peptidomics data are ideal for in silico identification of (neo-)antigens. The new motifs further reveal allosteric modulation of HLA-I binding specificity and we unravel the underlying mechanisms by protein structure analysis, mutagenesis and in vitro binding assays.
ligands and these data have been used to train machine learning algorithms for HLApeptide interaction predictions [4] [5] [6] [7] [8] [9] . However, the vast majority (>90%) of HLA-I alleles still lack documented ligands and despite algorithmic developments to generalize prediction methods to any allele 10 , it is more challenging to accurately describe motifs of alleles without known ligands.
Mass-spectrometry (MS) analysis of HLA binding peptides eluted from cell lines or tissue samples is a promising alternative to the use of HLA-ligand interaction predictions. Despite technical and logistic challenges (typically 1cm 3 of tissue material is required), MS is increasingly used to directly identify viral 11, 12 or cancerspecific (neo-)antigens [13] [14] [15] [16] [17] [18] , when experimentally feasible. Tens of thousands of endogenous peptides naturally presented on HLA-I molecules are identified in such HLA peptidomics studies, providing a unique opportunity to collect very large numbers of HLA ligands that could be used to better understand the binding properties of HLA-I molecules. The challenge in studying HLA-I motifs based on such pooled peptidomics data from unmodified cell lines or tissue samples is to determine the allele on which each peptide was displayed. While the most widely used approach is to predict binding affinity of each peptide to each allele present in a sample 19 , recent studies have suggested that HLA-I motifs could be identified in HLA peptidomics datasets in an unsupervised way by grouping peptides based on their sequence similarity 15, [20] [21] [22] . However, this strategy still relies on previous information about HLA-I binding specificity when associating predicted motifs with HLA-I alleles and is therefore restricted to alleles whose motifs have been already characterized.
Here, we show for the first time that dozens HLA-I motifs can be identified without any a priori information about HLA-I binding specificity by taking advantage of cooccurrence of HLA-I alleles across both newly generated and publicly available HLA peptidomics datasets. Our approach uncovers new motifs for several alleles for which, until this study, no known ligands had been documented and significantly improves neo-antigen predictions in five out of six tumor samples with experimentally determined neo-antigens. Our large and unbiased collection of HLA-I ligands further allows us to unravel some of the molecular determinants of HLA-I binding motifs and reveals allosteric modulation of HLA-I binding specificity. To elucidate the underlying molecular mechanisms, we show how a single point mutation in HLA-B14:02 outside of the P2 binding site significantly changes the amino acid preferences at P2 in the ligands.
Results

Fully unsupervised identification of HLA-I binding motifs
To study the properties of HLA-I alleles at a large scale and without relying on a priori knowledge about their binding specificity, we reasoned that HLA-I binding motifs might be identified across samples with in-depth and accurate HLA peptidomics data by taking advantage of co-occurrence of HLA-I alleles. Table 1 ).
The number of unique HLA-ligand interactions across all samples reaches 252,165
for a total of 119,035 unique peptides (9-to 14-mers), which makes it, to our knowledge, the largest currently available collection of HLA peptidomics datasets both in terms of number of peptides and diversity of HLA-I molecules. Binding motifs in each HLA peptidomics dataset were identified for 9-and 10-mers using a motif discovery algorithm initially developed for multiple specificity analyses 26, 27 and recently applied to the analysis of seven HLA peptidomics datasets 22 (see Supplementary Fig. 1 ). Importantly, this method does not rely on HLA-peptide interaction predictions (see Methods).
To assign each motif to its allele even in the absence of a priori information about the alleles' binding specificity, we developed the strategy illustrated in Fig. 1a . In this example coming from our newly generated HLA peptidomics data, one allele was shared between two samples (HLA-B38:01). Remarkably, exactly one identical motif was shared between the two samples. As such, one can predict that this motif corresponds to the shared allele. Similarly, if one sample shares all but one allele with another sample, it can be inferred that the motif that is not shared corresponds to the unshared allele (Fig. 1b ). These two ideas can then be recursively applied to identify HLA-I motifs across large HLA peptidomics datasets from all our different samples (see Methods). Of note, motifs identified in distinct samples that have some alleles in common show very high similarity ( Fig. 1 and Supplementary Fig. 1 ) and our new approach builds upon this remarkable reproducibility of in-depth and accurate HLA peptidomics data.
We applied our algorithm to our 50 HLA peptidomics datasets. In total, 44 different motifs could be associated with their corresponding allele without relying on any a priori knowledge of HLA-I binding specificity (Fig. 2a) . To validate our predictions, we compared the motifs predicted by our fully unsupervised method with known motifs derived from IEDB 28 . Despite some differences (e.g. HLA-A25:01 motif at P9), we observed an overall high similarity for most common alleles, confirming the very high accuracy of our predictions (Fig. 2a) . Moreover, seven alleles (HLA-B13:02, HLA-B14:01, HLA-B15:11, HLA-B15:18, HLA-B18:03, HLA-B39:24 and HLA-C07:04) for which our approach uncovered a clear motif did not have known ligands in IEDB, and an additional one (HLA-B56:01) had only three known ligands.
Semi-supervised approach
For the most frequent HLA-I alleles, a reasonable description of their binding motifs can be obtained from existing databases 28 . To further expand our collection of HLA-I binding motifs, we used similarity to the binding motifs derived from IEDB ligands to annotate motifs that could not be assigned to their corresponding allele by the fully unsupervised approach (see Methods). We then re-ran our algorithm on the remaining 3 ).
Investigating technical biases in HLA peptidomics studies
Different technical biases may affect MS data, which could undermine their use for training HLA-peptide interaction predictors. To investigate this potential issue, we computed amino acid frequencies at non-anchor positions (P4 to P7) in our HLA peptidomics data (see Methods and Supplementary Table 2 ). We observed a high correlation between amino acid frequencies at non-anchor positions in our HLA peptidomics data and in the human proteome (r=0.85) ( Fig. 3 and Supplementary Fig.   4 ). The most important difference was found for cysteine, which is rich in posttranslational modifications that are typically not included in database searches and was observed at very low frequency in the HLA peptidomics data. Other amino acids
were not much under-or over-represented, and no clear pattern emerged from these data with respect to amino acid biophysical properties (e.g., charge, hydrophobicity, size). Overall, our results suggest that HLA peptidomics data do not show strong technical biases, apart from under-representation of cysteine, and therefore provide ideal data for training HLA-peptide interaction predictors, especially for ligands coming from human cells like neo-antigens.
Predictions of neo-antigens in tumors
To test whether our unique dataset of naturally presented peptides could help predicting neo-antigens in tumors, we trained a predictor of HLA-ligands with these data. As MS only includes positive examples, we built Position Weight Matrices (PWMs) for each allele based on the peptides assigned to it across all our HLA peptidomics datasets. To account for the main bias in HLA peptidomics data, we further renormalized our predictions by amino acid frequencies observed at nonanchor positions (see Methods).
We then collected all available datasets that included direct identification with mass spectrometry of neo-antigens displayed on cancer cells as well as exome sequencing (Mel5, Mel8, Mel15 from 15 and 12T from 18 , for a total of ten 9-and 10-mers neoantigens, see Table 1 ). This dataset has the unique advantage of not being restricted to neo-antigens selected based on in silico predictions, and is therefore ideal for benchmarking neo-antigen prediction methods. Moreover, as these studies are quite recent, the neo-antigens are not part of the training set of any existing algorithm. We retrieved all possible 9-and 10-mer peptides that encompassed each missense mutation (Supplementary Dataset 3). We then ranked all these potential neo-antigens based on the score of our predictor (see Methods). Of note, HLA peptidomics data used to train our predictor only consist of wild-type human peptides and did not include any mutated peptide identified in our previous report 15 . Remarkably, eight out of the ten neo-antigens were best predicted by our predictor and seven of them fell among the top 20, indicating that by testing as few as 20 peptides per sample, we could identify more than two thirds of the neo-antigens found by MS ( Table 1 ).
Considering that the total number of potential neo-antigens (i.e. 9-and 10-mers containing a missense mutation) can be as large as 25,000 for tumors with high mutational load, our predictor trained on naturally presented human HLA ligands clearly enabled us to significantly reduce the number of peptides that would need to be experimentally tested to identify bona fide neo-antigens from exome sequencing data. Importantly, even if we did not include in the training of our predictor MS data from the samples in which the neo-antigens were identified, six neo-antigens were still well predicted (see Supplementary Table 3 ). When comparing with standard tools that are widely used to narrow-down the list of predicted neo-antigens 6,10,29 , our method trained on HLA peptidomics data showed clear improvement (Table 1) , even when restricting the number of potential neo-antigens to those predicted by NetMHC 6 ( Fig. 4a) . Nevertheless, both our predictor and standard prediction tools failed to identify some neo-antigens (e.g., KLILWRGLK from NCAPG2 P333L mutation, see Table 1 ) 15 . This suggests that, when enough tumor material is available for immunopeptidomics analyses, direct identification of neo-antigens with MS should still be performed to optimally enrich in true positives the list of ligands to be experimentally tested for immunogenicity 17 . As a second independent validation for our predictions we used the neo-antigens recently identified in two lung cancer Table 4 and Methods).
Analysis of the newly identified motifs
One of our novel HLA-I motifs describes the binding specificity of HLA-A02:20
( Fig. 6b ). Among them, HLA-B14:02 had the highest sequence similarity to HLA-B15:18, with only 8 different residues in the peptide binding domain. Structural inspection of the non-conserved residues showed that none make any contact with arginine at P2 in the crystal structure of HLA-B14:02 (orange residues in Fig. 5c ). This suggests that the difference in binding specificity at P2
between HLA-B14:02 and HLA-B15:18 is likely explained by allosteric mechanisms.
Of particular interest is residue 121 (W in HLA-B14:02 and R in HLA-B15:18), which is more than 7Å away from the arginine sidechain at P2 and is part of a network of aligned aromatic residues (Y33, W121 and F140) in HLA-B14:02 (Fig.   5c ). We hypothesized that mutating this residue into arginine in HLA-B14:02 may modify the binding specificity to accommodate histidine at P2.
Molecular mechanism underlying allosteric modulation of HLA-I binding specificity
To test our hypothesis, we generated a construct for HLA-B14:02 wild-type (wt) and W121R mutant. We tested several ligands of HLA-B15:18 identified in our HLA peptidomics data with histidine at P2, which were predicted to show enhanced binding to HLA-B14:02 W121R. As expected, a strong decrease in binding stability was observed between HLA-B14:02 W121R and HLA-B14:02 wt (Fig. 5d) .
Reversely, when testing the same peptides with arginine at P2, a significant increase in stability was observed between HLA-B14:02 W121R and HLA-B14:02 wt (Fig.   5d ). For instance, binding of the peptide AHTKPRPAL was fully abolished in HLA-B14:02 wt, but was rescued when changing histidine to arginine at P2. Although other residues may also play a role in the binding specificity differences between of HLA-B14:02 and HLA-B15:18, all of them are further away from P2, which supports the allosteric hypothesis. Overall, our results show that HLA-I binding specificity at P2
can be modulated by amino acids outside of the P2 binding site.
Discussion
Despite decades of work to characterize the binding motifs of the most common HLA-I alleles, in-depth unbiased peptide screening approaches are not commonly used. This is mainly because both the N-and the C-terminus of the peptides are engaged in binding to HLA-I molecules, thereby preventing the use of highthroughput techniques for peptide screening like phage display or peptide arrays.
Here, for the first time, we show that in-depth and accurate HLA peptidomics data from unmodified cell lines and tissue samples together with novel machine learning algorithms enable us to rapidly identify thousands of new HLA-I ligands in a fully unsupervised way and characterize the binding properties of HLA-I alleles that had no known ligands until this study. Remarkably, our predicted motifs displayed high similarity with known motifs for common alleles and very little technical biases. This suggests that HLA peptidomics data are optimal to train HLA-ligand interaction predictors, as confirmed by our ability to accurately predict many neo-antigens identified by mass spectrometry in tumor samples. Although mass spectrometry may miss a fraction of the actually presented and immunogenic neo-antigens, those detected by MS are likely presented at high level on cancer cells. Therefore, accurately predicting such dominant neo-antigens is promising to prioritize targets for cancer immunotherapy. Importantly, the improvement in neo-antigen prediction accuracy appears to come primarily from better motifs. For instance, differences are observed at P9 between the motif of HLA-A25:01 derived from our study (preference (Fig. 2a) . This likely explains why the neo-antigen ETSKQVTRW was poorly predicted by standard tools 6, 10 (predicted IC 50 > 3,000nM). Moreover, as our predictor is only trained on naturally presented ligands, it may also capture some features of antigen presentation of endogenous peptides beyond the sole binding to HLA molecules. Along this line, it is interesting to note that a less important improvement in predictions had been observed when attempting to predict epitopes from the SYFPEITHI database 32 (including a large fraction of viral peptides) with HLA peptidomics data 22 . Although the dataset used in this previous study was significantly smaller, this observation suggests that HLA peptidomics data may be especially well suited for training predictors of human endogenous or mutated HLA ligands. Overall, our work highlights the importance of carefully determining HLA-I motifs based on unsupervised analysis of naturally presented human HLA ligands for neo-antigen discovery.
Results shown in Fig. 5 further emphasize the power of in-depth sampling of the HLA-I ligand space to inform us about molecular mechanisms underlying HLA-I binding properties 33 . Considering the rapid expansion of HLA peptidomics experiments performed in cancer immunotherapy research [14] [15] [16] 18, 24, 25 , we anticipate that our novel approach for HLA-I motif identification will enable similar analyses in the future to uncover other molecular determinants of HLA-I binding specificity.
Our algorithm does not require motifs corresponding to each allele to be identified.
For instance in Fig. 1a , only five motifs were found in the first sample (GD149), while this sample had six different alleles. This is a frequent situation when analysing HLA peptidomics data with unsupervised approaches 22, 34 . As previously observed, it affects especially HLA-C alleles which are often poorly expressed and are more redundant 22, 35 ( Supplementary Fig. 1) .
Overall, our work shows for the first time that HLA-I motifs can be reliably identified across in-depth and accurate HLA peptidomics datasets without relying on peptide-HLA interaction prediction tools or a priori knowledge of HLA binding specificity. 
Methods
Cell lines and antibodies
We carefully selected ten donors expressing a broad range of HLA-I alleles and generated novel HLA peptidomics data (Supplementary Table 1 
LC-MS/MS analysis of HLA-I peptides
Measurements of HLA-I peptidomics samples were acquired using the nanoflow UHPLC Easy nLC 1200 (Thermo Fisher Scientific, Germering, Germany) coupled online to a Q Exactive HF Orbitrap mass spectrometer (Thermo Fischer Scientific, Bremen, Germany) or with Dionex Ultimate RSLC3000 nanoLC (Thermo Fischer Scientific, Sunnyvale, CA) coupled online to an Orbitrap Fusion Mass Spectrometer (Thermo Fischer Scientific, San Jose, CA), both with a nanoelectrospray ion source.
We packed an uncoated PicoTip 8µm tip opening with diameter of 50 cm x 75 um with a ReproSil-Pur C18 1.9 µm particles and 120 Å pore size resin (Dr. Maisch
GmbH, Ammerbuch-Entringen, Germany) re-suspended in Methanol. The analytical column was heated to 50°C using a column oven. Peptides were eluted with a linear gradient of 2-30% buffer B (80% ACN and 0.1% formic acid) at a flow rate of 250 nl/min over 90 min.
Data was acquired with data-dependent "top10" method, which isolates the ten most intense ions and fragments them by higher-energy collisional dissociation ( 
Data analysis of HLA-I peptides
We employed the MaxQuant computational proteomics platform 41 false discovery rate of 0.01 was required for peptides and no protein false discovery rate was set. The enzyme specificity was set as unspecific. Possible sequence matches were restricted to 8 to 15 amino acids, a maximum peptides mass of 1,500 Da and a maximum charge state of three. The initial allowed mass deviation of the precursor ion was set to 6 ppm and the maximum fragment mass deviation was set to 20 ppm.
We enabled the 'match between runs' option, which allows matching of identifications across different replicates of the same biological sample in a time window of 0.5 min and an initial alignment time window of 20 min.
Publicly available HLA-I peptidomics data
To expand the number of samples and survey an even broader range of HLA-I alleles, we included in this study forty publicly available HLA peptidomics data from seven recent studies 15, 16, 20, 21, [23] [24] [25] . Only samples with HLA-I typing were used. Peptides identified in the recent study 16 in different repeats and under different treatments were pooled together to generate one list of unique peptides per sample. Since the published peptidomics datasets from Pearson et al. 25 were filtered to include only peptides with predicted affinity scores of less or equal to 1250 nM, we re-processed the mass spectrometer raw data using MaxQuant with similar settings as mentioned above except that peptide length was set to 8-25 mers (Supplementary Dataset 2).
IEDB data
Known HLA-I ligands were retrieved from IEDB (mhc_ligand_full.csv file, as of October 5, 2016) 28 . All ligands annotated as positives with a given HLA-I allele (i.e., "Positive-High", "Positive-Intermediate", "Positive-Low" and "Positive") were used to build the IEDB reference motifs (Fig. 2) . Ligands coming from HLA peptidomics studies analysed in this work were not considered to prevent circularity in the motif comparisons and because the HLA-I alleles to which these peptides bind were not experimentally determined. Position Weight matrices (PWMs) representing binding motifs in IEDB and used to compare with motifs derived from our deconvolution of HLA peptidomics datasets were built by computing the frequency of each amino acid at each position and using a random count of 1 for each amino acid at each position.
Mixture model for HLA-I binding motifs identification in HLA peptidomics data
An algorithm based on mixture models and initially developed for multiple specificity analysis in peptide ligands 26, 27 was used to identify binding motifs in each dataset analysed in this work. Briefly, all peptides pooled by mass spectrometry analysis of eluted peptide-HLA complexes in a given sample were first split into different groups according to their size (9-10 mers). All 9-and 10-mers ligands were then modelled using multiple PWMs 22 . The results of such analysis consist of a set of PWMs that describe distinct motifs for each HLA peptidomics datasets (see Supplementary Fig.   1 ) and probabilities (i.e., responsibilities) for each peptide to be associated with each motif.
Fully unsupervised deconvolution of HLA peptidomics datasets
The availability of high-quality HLA peptidomics data from several samples with diverse HLA-I alleles suggest that one could infer which motifs correspond to which HLA-I alleles without relying on comparison with known motifs. For instance, if two samples share exactly one HLA-I allele, it is expected that the shared motif will originate from the shared allele (Fig. 1a) . To exploit this type of patterns of shared HLA-I alleles, we designed the following algorithm:
1) For each allele present in at least two samples, find all samples that share only this allele (e.g., HLA-B38:01 in Fig. 1a ). Identify the shared motif. If a shared motif is found, map this motif to the corresponding allele in each sample.
2) Find samples that share all except one allele with another sample (e.g., HLA-A24:02 in Fig. 1b) . Find the motif that is not shared and map it to the HLA-I allele that is not shared.
3) Check if some samples contain exactly one motif and one allele that have not yet been associated. Annotate the remaining motif to the corresponding allele.
4) Use the motifs mapped to HLA-I alleles in steps 1), 2) and 3) to identify them in other samples that contain these alleles based on motif similarity.
5) Go back to 1) until no new motif can be mapped to HLA-I alleles.
Comparison of motifs was performed using Euclidean distance between the corresponding PWMs:
, where M and M' stands for two PWMs (i.e., 20 x L matrices) to be compared and L is the peptide length. A threshold of = 0.078 was used to define similar motifs based on visual inspection.
Cases of inconsistencies (i.e., distances larger that T) between motifs mapped to the same allele were automatically eliminated. The final binding motifs for each HLA-I allele (Fig. 2a) were built by combining peptides from each sample that had been associated with the corresponding allele.
In practice, HLA-A and HLA-B alleles tend to be more expressed and therefore give rise to a stronger signal in HLA peptidomics data. We therefore used first our deconvolution method 22 , setting the number of motifs equal to the number of HLA-A and HLA-B alleles and identified HLA-A and HLA-B motifs with the algorithm introduced above (Step 1). We then ran the deconvolution method of 22 without restricting the number of clusters (
Step 2) and identified motifs corresponding to HLA-A and HLA-B alleles based on the similarity with those identified in Step 1. The remaining motifs were then analysed across all samples with the algorithm introduced above.
Semi-supervised deconvolution of HLA peptidomics datasets
To expand the identification of binding motifs for alleles without known ligands, we used data from IEDB for HLA-I alleles with well-described binding motifs. In practice, for all HLA-I alleles in our samples that had not been mapped to motifs in the fully unsupervised approach and have more than twenty different ligands in IEDB,
PWMs were built from IEDB data. These PWMs were used to scan the remaining motifs in each sample that contained the corresponding alleles. Motifs were mapped to HLA-I alleles if exactly one PWM obtained with the mixture model was found to be similar to the IEDB-derived motif (i.e., Euclidean distance smaller than T, as before). The unsupervised procedure described above was then applied to the remaining motifs to identify new motifs for alleles without ligands in IEDB.
Amino acid frequencies at non-anchor positions in HLA peptidomics datasets
To have reliable estimates of the potential technical biases due to MS, amino acid frequencies were computed at non-anchor positions (P4 to P7) for alleles in our HLA peptidomics datasets (9-mers). Alleles showing some specificity at these positions analysis. The average frequencies of amino acids across alleles were then compared against the human proteome using Pearson correlation coefficient (Fig. 3) . We also performed the same analysis with HLA-I ligands (9-mers) from IEDB splitting between those obtained by MS and those obtained by other assays ("non-MS data") (see Supplementary Fig. 4 ). To enable meaningful comparison between these datasets, only alleles present in our HLA peptidomics data, with more than 100 ligands in both IEDB MS and non-MS data were considered in this analysis (14 alleles in total, see Supplementary Fig. 2 ).
Prediction of neo-antigens
For each HLA-I allele, PWMs were built from all peptides associated to this allele across all samples where the binding motif could be identified, using the highest responsibility values of the mixture model 22 . The frequency of each amino acid was first computed. Pseudocounts were added using the approach described in 42 , based on the BLOSUM62 substitution matrix with parameter β=200. The score of a given peptide (X 1 ,…X N ) was computed by summing the logarithm of the corresponding PWM entries, including renormalization by expected amino acid frequencies:
). Here ! stands for frequency of amino acid A at non-anchor positions ( Fig. 3 and Supplementary Table 2 ), !,! stands for the PWM entry corresponding to amino acid A at position i, and N stands for the length of the peptide (N=9,10). The final score of a peptide was taken as the maximal score across all alleles present in a given sample and a p-value estimate was computed by comparing with distribution of scores obtained from 100,000 randomly selected peptides from the human proteome.
To test our ability to predict neo-antigens, we used four melanoma samples in which identified by exome sequencing in those four melanoma samples 15 were retrieved and a list of all possible 9-and 10-mer peptides encompassing each mutation was built (Supplementary Dataset 3). Multiple transcripts corresponding to the same genes were merged so that each mutated peptide appears only once in the list. The total number of potential neo-antigens in each sample is shown in Table 1 . Predictions for each HLA-I allele of each sample were carried out with the model described above. Peptides were ranked based on the highest score over the different alleles present in their sample. In parallel, affinity predictions with NetMHC (v4.0) 6 and NetMHCpan (v2.8)
Curves were also calculated by restricting to potential neo-antigens that passed the widely used 500nM threshold on NetMHC predictions 6 (Fig. 4a) . The experimentally identified neo-antigens ETSKQVTRW (Mel5 predicted best IC 50 = 3231nM with HLA-A25:01) and DANSFLQSV (12T, predicted best IC 50 = 6235nM with HLA-B51:01) did not pass this affinity threshold and were added to the lists.
The same analysis was applied to study neo-antigens (9-and 10-mers) recently identified in two lung cancer patients 30 (L011: FAFQEYDSF, GTSAPRKKK, SVTNEFCLK, RSMRTVYGLF, GPEELGLPM and L013: YSNYYCGLRY, ALQSRLQAL, KVCCCQILL). In this study, only mutated peptides with a predicted binding affinity < 500nM were tested for T-cell reactivity. From the list of missense mutations, we therefore extracted all such mutated peptides potentially binding to one HLA-I allele and ranked with our predictor as well as other tools those experimentally found to be immunogenic (Fig. 4b) .
The standalone command-line programme MixMHCpred to run these predictions is provided free of charge for academic users to run predictions with the model trained on HLA peptidomics data, including 19 additional alleles with MS data in IEDB but not present in our datasets to further expand the coverage of HLA alleles to 71.
Predictions of neo-antigens in melanoma samples -cross-patient validation
To assess how much our improved predictions of neo-antigens in the three melanoma samples of 15 depend on HLA peptidomics data generated from these samples, we performed a careful cross-sample validation. For each of the three samples where neoeptiopes had been identified (Mel15, Mel8, Mel5) 15 , we re-run our entire pipeline (i.e., identification of HLA-I motifs across HLA peptidomics datasets + construction of PWMs for each allele) without the HLA peptidomics data coming from this sample. The PWMs were then used to rank all possible peptides (9-and 10-mers) encompassing each mutation. Overall, the predictions change very little, especially for neo-antigens with verified immunogenicity (Supplementary Table 3 ). In one case (ETSKQVTRW for Mel5), our method failed. This is because HLA-A25:01 was only present in Mel5 and therefore no longer identified by our algorithm when removing HLA peptidomics data from Mel5. Of note, this peptide was not well predicted by other methods 6, 10, 29 either.
Analysis of HLA sequences and structures
HLA-I sequences were retrieved from IMGT database 3 . All protein structures analysed in this work were downloaded from the PDB. Residues forming the P2 binding site in HLA-B14:02 (PDB: 3BVN 43 ) were determined using a standard cutoff of 5Å from any heavy atoms of arginine at P2. Fig. 5d ).
Binding
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